Michael Grable
Urology · Deland, FLNPI 1588614374
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 45 manufacturers reported payments, led by Johnson & Johnson at 35.9% of the total. Reporting peaked in 2019 at $12,085 and has fallen 99.8% since, to $21 in 2024.
Across 297 payments — averaging $67.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$7K
- Urogpo LLC$4K
- Bayer$3K
- Astellas Pharma US Inc$1K
- Dendreon Pharmaceuticals LLC$787
- Endo Pharmaceuticals Inc.$382
- plus $3K from 39 others
Across 95 payments — averaging $2064.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$111K
- Dendreon Pharmaceuticals LLC$70K
- Astellas Pharma Global Development$9K
- Bayer$6K
What the payments were for
- Consulting fees$9,07545%
- Travel & lodging$3,39317%
- Food & beverage$7,51937%
- Education$1161%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,103 in reported general payments places this provider in the 85th percentile of 935 urology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 41 | $25,256 |
| GemtesaVibegron | 20 | $14,100 |
| Tamsulosin Hcl | 207 | $3,906 |
| Finasteride | 164 | $2,253 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 31 | $751 |
| Solifenacin Succinate | 23 | $688 |
| Doxazosin Mesylate | 11 | $293 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $1,331 | $25,25641 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $20 | $14,10020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 935 urology providers in Florida.
Other urology in Deland
- Paul PeritoCoral Gables$3.6M
- Scott SellingerTallahassee$2.3M
- Mark Anthony GonzalgoMiami$1M
- Edward GheilerHialeah$655K
- Rolando RiveraNaples$437K
- Matthew ErcolaniVenice$416K
- Olubayo TojuolaOrlando$283K
- Juan SuarezCoral Gables$276K
- Michael McDonaldCelebration$272K
- Raymond PakJacksonville$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.